Dr Agarwal’s Merger: Nov 18 Record Date Set

Board confirms the merger timetable

Dr. Agarwal’s Health Care Limited has fixed November 18, 2026 as the record date for its amalgamation with Dr. Agarwal’s Eye Hospital Limited. The announcement followed a board meeting held on October 20, 2026. The scheme is set to become effective and operative from November 1, 2026. Dr. Agarwal’s Eye Hospital is the transferor company under the arrangement, while Dr. Agarwal’s Health Care is the transferee company. The record date will identify shareholders eligible to receive consideration shares under the approved scheme. The filing is a material update following the approval of the merger by the National Company Law Tribunal, Chennai Bench.

NCLT approval cleared the arrangement

The NCLT, Chennai Bench sanctioned the scheme of amalgamation between the two companies. The sanction order was pronounced on September 30, 2026 and was uploaded to the NCLT website on October 5, 2026. The tribunal approval covered the scheme involving the companies and their respective shareholders and creditors. Completion of the regulatory and procedural conditions allowed the boards to determine the effective date and record date. The October 20 board update stated that the conditions required for the scheme’s effectiveness had been satisfied. The merger will therefore operate from November 1, subject to the terms set out in the approved scheme.

Appointed date remains April 1, 2026

The appointed date for the amalgamation is April 1, 2026, defined as the opening of business on that date. This date is distinct from the effective date of November 1, 2026. The appointed date establishes the date from which the scheme takes effect for the purposes set out in the arrangement. The effective date reflects the completion of the approvals and actions needed to implement it. The companies disclosed both dates in their regulatory updates. This distinction is relevant for shareholders tracking the legal completion of the merger and the scheme’s stated operational timeline.

Shareholders will receive shares under a 23:2 ratio

Eligible equity shareholders of Dr. Agarwal’s Eye Hospital as of the November 18 record date will receive consideration shares of Dr. Agarwal’s Health Care. The approved share exchange ratio is 23 equity shares of face value Re 1 each in Dr. Agarwal’s Health Care for every two equity shares of face value Rs 10 each held in Dr. Agarwal’s Eye Hospital. The consideration will be allotted to shareholders identified on the record date. The announcement does not provide a separate payment component. Shareholders of the transferor company will receive shares in the transferee company in exchange for their existing holdings under the scheme.

Key merger dates and terms

Capital structure will be expanded

Following the amalgamation, Dr. Agarwal’s Health Care’s authorised share capital will increase from Rs 90 crore to Rs 110 crore. The increase supports the issue of consideration shares under the approved exchange ratio. The filing identifies this capital change as part of the merger implementation. No additional financial terms, valuation details, or revised ownership figures were stated in the supplied announcement. Investors will primarily need to follow the record-date process and the allotment of shares to eligible Dr. Agarwal’s Eye Hospital shareholders. The corporate action consolidates the relevant entities within the group’s eye-care operations.

Consolidation brings the eye-care business together

The transaction combines Dr. Agarwal’s Eye Hospital with Dr. Agarwal’s Health Care under the latter entity. The disclosed purpose is to consolidate the group’s eye-care footprint into a single entity. The combined business had trailing twelve-month revenue of Rs 2,207 crore, according to the merger-related information provided with the announcement. The revenue figure offers context on the scale of the operating platform being brought together. However, the announcement did not disclose merger-related cost savings, earnings impact, or post-merger operational targets. Those outcomes should not be assumed from the corporate action alone.

What the record date means for investors

The November 18 date is important for shareholders of Dr. Agarwal’s Eye Hospital because eligibility for consideration shares will be determined on that date. Investors holding the transferor company’s shares on the record date will receive Dr. Agarwal’s Health Care shares based on the 23:2 exchange ratio. The announcement does not state a market-price impact, trading impact, or a timetable for the credit of new shares. It also does not provide a revised listing or trading schedule. The immediate confirmed event is the identification of eligible shareholders for allotment under the scheme.

Market impact and financial context

The merger announcement provides a defined legal and corporate-action timeline rather than new operating guidance. Its direct financial terms include the share exchange ratio and the increase in authorised share capital from Rs 90 crore to Rs 110 crore. The disclosed trailing twelve-month revenue of Rs 2,207 crore indicates the scale of the combined eye-care platform. No figures were provided for profit, debt, merger expenses, expected synergies, or earnings per share. As a result, the filing does not support conclusions on the transaction’s future financial effect beyond the stated consolidation and share issuance mechanics.

Next steps after the record date

The scheme will become effective on November 1, 2026, ahead of the November 18 record date. Dr. Agarwal’s Health Care will then determine eligible Dr. Agarwal’s Eye Hospital shareholders for the allotment of consideration shares. The transaction follows the NCLT sanction and the October 20 board decision on implementation dates. The key confirmed milestones are now the scheme’s effective date, the record date, and the subsequent share allotment process. Shareholders should refer to company and exchange filings for any further notices on allotment, credit of shares, or related corporate-action procedures.